For the treatment of Osteogenesis Imperfecta (“OI”)
Lead indication: The treatment of severe Alpha-1 Antitrypsin Deficiency (“AATD”). Investigator led studies into additional indications ongoing.
For the treatment of platinum-resistant ovarian cancer. Navicixizumab has been partnered with OncXerna Therapeutics Inc. for further development.
For the treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”).
Mereo BioPharma today announced updated clinical data from its open-label Phase 1b/2 Study of Etigilimab and Nivolumab in subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE). The data will be presented in a poster session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting on June 5, 2022. The Company also provided an update on its capital allocation and portfolio prioritization plan.
Mereo BioPharma today announced the presentation of interim clinical data from its Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors in a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3 – 7, 2022 in Chicago IL.
Mereo BioPharma announces positive topline results from ASTRAEUS a Phase 2 trial of alvelestat in Alpha-1 Antitrypsin Deficiency- associated Emphysema.
Mereo BioPharma Group plc today announced it will host a conference call on Monday, May 9, 2022 at 10:30 a.m. ET to review top-line clinical data from its “ASTRAEUS” Phase 2 Study of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema.